Scholarlink

<p>We here report on a patient with relapsed-refractory multiple myeloma (RRMM) who received chimeric antigen receptor (CAR) T-cells (Ciltacabtagene Autoleucel, cilta-cel, Carvykti<sup>®</sup>) after achieving a partial but not durable remission with Idecabtagene Vicleucel (ide-cel, Abecma<sup>®</sup>). Both CAR T-cells target the B-cell maturation antigen (BCMA) and their sequential use is as yet rare, thus data on safety and efficacy of their sequential employment are precious and relevant for the myeloma commmunity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月1日

查看全文
  • Paul Mobascher,
  • Monika Engelhardt,
  • Ralph Wäsch

摘要

We here report on a patient with relapsed-refractory multiple myeloma (RRMM) who received chimeric antigen receptor (CAR) T-cells (Ciltacabtagene Autoleucel, cilta-cel, Carvykti®) after achieving a partial but not durable remission with Idecabtagene Vicleucel (ide-cel, Abecma®). Both CAR T-cells target the B-cell maturation antigen (BCMA) and their sequential use is as yet rare, thus data on safety and efficacy of their sequential employment are precious and relevant for the myeloma commmunity.